ClinicalTrials.gg
RecruitingNCT07260175adIVOUpdated Aug 12, 2026

Phase II Study Evaluating Ivosidenib Maintenance After SOC Adjuvant Chemotherapy in Curative mIDH1 Cholangiocarcinoma

A Phase 2 interventional study of Ivosidenib in Cholangiocarcinoma and IDH Mutation, sponsored by Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest. Recruiting at 15 sites in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-12.

Sponsored by Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest · Phase 2, Interventional, and Treatment

How we know · 3 judgments

From the registry’s dates

  • Started Nov 2025; still recruiting 1 year later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
40
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 62 studies in Cholangiocarcinoma with a site in Germany — 12 open to participants now, 23 under way, 5 of them phase 3. Cholangiocarcinoma · Germany.

Planned enrollment
40th of 55
40 · median 128
Started
2025
with 2 others
Phase 2
24 of 62
3 open now
Primary completion
2030-12
later than 21 of 22 live
Registered
60th of 62
by date
Lead sponsor
9 of 62
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest

Among the 62 studies in Cholangiocarcinoma with a site in Germany, this one is the 40th largest by planned enrollment of the 55 interventional ones that give a count, is one of 3 that started in 2025, is one of 24 in phase 2, reaches primary completion later than 21 of the 22 other live ones, and was the 60th registered.

Cholangiocarcinoma

826 studies on the registry are indexed under Cholangiocarcinoma; 289 are open to participants now.

Browse Cholangiocarcinoma studies →

Open to participants now

12 of the 62 studies in Cholangiocarcinoma with a site in Germany are open now. Recruiting first, the newest first:

6 more — sign in →

All 12 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 211 Cholangiocarcinoma studies recruiting now, 141 (67%) set no upper age limit and 49 (23%) stop at 75 or younger; 10 take children under 18; 14 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 62 studies in Cholangiocarcinoma with a site in Germany, or all of them as a file.
02

Study summary

This study trial is a prospective, multicentre, exploratory, single-arm, open-label phase II study to evaluat ivosidenib maintenance after SOC adjuvant chemotherapy in curative mIDH1 cholangiocarcinoma

Read the detailed description

The primary objective is to assess the efficacy of ivosidenib maintenance directly after adjuvant SOC chemotherapy in curative mIDH1 iCCA. The corresponding endpoint ist 1-year recurrence-free survival rate (RFS@1year), defined as proportion of patients alive with no disease recurrence 1 year after start of maintenance ivosidenib.

The secondary objective is to evaluate further efficacy as well as to assess safety and impact on the quality of life of ivosidenib maintenance directly after adjuvant SOC chemotherapy in curative mIDH1 iCCA. The corresponding endpoint are:

  • RFS, defined as time from start of ivosidenib maintenance to the date of disease recurrence or death to any cause
  • Time to recurrence (TTR), defined as time from start of ivosidenib maintenance to the date of disease recurrence
  • Time to treatment failure (TTF), defined as time from start of ivosidenib maintenance to the date of premature treatment discontinuation from any cause, including disease recurrence, treatment toxicity or death
  • Overall survival (OS), defined as time from enrollment to the date of death from any cause
  • Safety
  • Quality of life using EORTC QLQ-C30 and EORTC QLQ-BIL21 questionnaires

This is a prospective, multi-center, exploratory, single-arm, open-label phase II study.

Patients with curatively resected intrahepatic cholangiocarcinoma with proven IDH1 mutation, without metastatic spread, in the adjuvant situation (R0-resected), who received 6 months of SOC adjuvant treatment and show at least stable disease under this treatment will be enrolled.

All eligible patients will receive ivosidenib (500 mg qd, 28 days). Patients will be treated within the trial for up to 12 months and the treatment response will be assessed every 8 weeks (Q8W ± 7 days) during trial treatment and every 12 weeks (Q12W ± 14 days) during follow-up until recurrence. Overall, patients will be followed up for 48 months after last patient in or until death, withdrawal of consent, or loss to follow-up (whichever occurs first).

03

Conditions studied

  • Cholangiocarcinoma
  • IDH Mutation

Browse trials for

Keywords

  • mIDH1 cholangiocarcinoma
  • ivosidenib maintenance
  • cholangiocarcinoma
  • R0-resection
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patient* provides signed .
  2. Patient is ≥ 18 years at the time of given informed consent.
  3. Patient has documented curatively resected intrahepatic cholangiocarcinoma, without spread, in the adjuvant situation (R0-resected)
  4. Patient has proven IDH1 mutation (IDH1-variant status evaluated locally by certified test on formalin-fixed paraffin-embedded tumor tissue specimen. If local testing for screening is not possible per local standard, tumor tissue samples will be subject to pre-screening via central IDH1 dPCR)
  5. Patient finished systemic SOC chemotherapy (with regimens allowed per the protocol) directly prior to trial inclusion.
  6. Radiologic imaging available that shows that patient is tumor free at the timepoint of enrollment (not older than 6 weeks from the day of inclusion).
  7. Patient has Performance status ≤ 1
  8. Hematological, hepatic and renal function parameters adequate to allow targeted therapy with ivosidenib at investigator´s discretion and IB.
  9. Patient has adequate coagulability to allow targeted therapy with ivosidenib at investigator´s discretion and IB. Patients receiving warfarin / Phenprocoumon must be switched to low molecular weight heparin and before starting trial-specific.
  10. Patient must be willingly to provide liquid samples, archival tumor tissue samples (if available), and in the event of disease recurrence, re-biopsy samples (if re-biopsy is considered safe for the patient) for the translational research program.
  11. Female patients of or male patients with female partners of childbearing potential must agree to remain abstinent (refrain from heterosexual intercourse) or use methods that result in a failure rate of \<1% per year during the treatment period and for at least 6 months after the last dose of trial treatment. Male patients with a pregnant partner must agree to remain abstinent or to use a condom for the duration of the pregnancy. Female patients of child-bearing potential must have a negative pregnancy test within the last 7 days prior to the start of trial therapy.
  12. Patient is willing and able to comply with the protocol (including contraceptive measures) for the duration of the trial including undergoing treatment and scheduled visits and examinations including follow up.

Exclusion criteria

Exclusion Criteria:

  1. Patient has a or R+ resected biliary tract cancer.
  2. Patient received previous therapy with an IDH1 inhibitor.
  3. Patient has known presence of tumors other than intrahepatic cholangiocarcinoma or a secondary tumor other than squamous or basal cell carcinomas of the skin or in situ carcinomas of the cervix which have been effectively treated. The sponsor decides to include patients who have received curative treatment and have been disease-free for at least 5 years.
  4. Simultaneous, ongoing systemic immunotherapy, chemotherapy, or hormone therapy not described in the trial protocol.
  5. Patient receives simultaneous treatment with a different anti-cancer therapy other than that provided for in the trial (excluding palliative radiotherapy only for symptom control).
  6. Patient has a stage B cirrhosis according to criteria (or worse) or cirrhosis (of any grade) with a history of hepatic encephalopathy or ascites resulting from cirrhosis. Clinically significant ascites is defined as ascites resulting from cirrhosis requiring diuretics or paracentesis.
  7. Patient has known allergic / hypersensitive reactions to at least one of the treatment components.
  8. Patient has other serious illnesses or medical ailments within the last 12 months prior to the start of the trial.
  9. Patient has a known presence of an active, uncontrollable infection.
  10. Patient has > 480ms or other factors that, in the discretion of the investigator increase significantly the risk of QT prolongation or arrhythmic events (e.g. heart failure, hypokalemia, family history of long QT syndrome). NOTE: Medications that prolong the QT interval should be avoided, unless they can be transferred to other medication within ≥ 5 half-lives to dosing or unless the medications can be properly monitored during the study. (If equivalent medication is not available, QTc should be closely monitored).
  11. Patient has active disseminated intravascular coagulation.
  12. Patient has an active disease that has required systemic treatment in the past 2 years (i.e. with use of disease modifying agents, or drugs). Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment.
  13. Patient has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial drug.
  14. Patient has any other serious concomitant or medical condition that, in the opinion of the investigator, presents a high risk of complications to the patient or reduces the likelihood of clinical effect. NOTE: strong inducers or sensitive CYP3A4 substrates with narrow therapeutic window should be avoided, unless they can be transferred to alternative medication within at least 5-half lives prior to dosing.
  15. Female patient is pregnant or breast feeding or planning to become pregnant within and 6 months after the end of treatment.
  16. Patient who has been incarcerated or involuntarily institutionalized by court order or by the authorities.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    Ivosidenib maintenance

    Ivosidenib maintenance after SOC adjuvant chemotherapy in curative mIDH1 cholangiocarcinoma

    Drug: Ivosidenib

Interventions

  • Ivosidenib (daily 500 mg) maintenance after SOC adjuvant chemotherapy in curative mIDH1 cholangiocarcinoma

    Also known as: Ivosidenib Pill (daily 500 mg)

06

What researchers measure

Primary outcomes

  1. recurrence-free survival rate

    1-year recurrence-free survival rate (RFS@1year), defined as proportion of patients alive with no disease recurrence 1 year after start of maintenance ivosidenib

    Time frame: 1-year

Secondary outcomes

  1. recurrence-free survival

    RFS, defined as time from start of ivosidenib maintenance to the date of disease recurrence or death to any cause

    Time frame: at 66 months

  2. Time to recurrence

    Time to recurrence (TTR), defined as time from start of ivosidenib maintenance to the date of disease recurrence

    Time frame: after 66 months

  3. Time to treatment failure (TTF)

    Time to treatment failure (TTF), defined as time from start of ivosidenib maintenance to the date of premature treatment discontinuation from any cause, including disease recurrence, treatment toxicity or death

    Time frame: at 66 months

  4. Overall survival

    Overall survival (OS), defined as time from enrollment to the date of death from any cause

    Time frame: at 66 months

  5. Safety (adverse events)

    frequency of adverse events

    Time frame: at 66 months

  6. Patient´s Quality of life

    Quality of life using EORTC QLQ-C30

    Time frame: at 66 months

  7. Patient´s Quality of Life

    Quality of life using EORTC QLQ-BIL21

    Time frame: at 66 months

07

Study locations

15 of 15 sites recruiting
  • Uniklinik RWTH Aachen
    Aachen, 52074, Germany
    Recruiting
    • Marie-Luise Berres, Prof. Dr. · Contact
  • Universitätsklinikum Bonn
    Bonn, 53127, Germany
    Recruiting
    • Maria Gonzalez-Carmona, Prof. Dr. · Contact
  • Uniklinikum Essen
    Essen, 45147, Germany
    Recruiting
    • Stefan Kasper-Virchow, Prof. Dr. · Contact
  • Krankenhaus Nordwest
    Frankfurt, 60488, Germany
    Recruiting
    • Thorsten O Goetze, Prof. Dr. · Contact
  • Universitätsklinikum Frankfurt
    Frankfurt, 60590, Germany
    Recruiting
    • Jörg Trojan, Prof. Dr. · Contact
  • Universitätsklinik Gießen und Marburg GmbH Standort Gießen
    Giessen, 35392, Germany
    Recruiting
    • Thomas Wehler, Prof. Dr. · Contact
  • Universitätsmedizin Göttingen
    Göttingen, 37099, Germany
    Recruiting
    • Johanna Reinecke, Dr. · Contact
  • Asklepios Tumorzentrum Hamburg
    Hamburg, 22763, Germany
    Recruiting
    • Dirk Arnold, Prof. · Contact
  • Uniklinikum Jena
    Jena, 7747, Germany
    Recruiting
    • Udo Lindig, Dr. · Contact
  • Universitätsmedizin Mainz
    Mainz, 55131, Germany
    Recruiting
    • Arndt Weinmann, Prof. Dr. · Contact
  • Universitätsklinikum Mannheim
    Mannheim, 68167, Germany
    Recruiting
    • Nadine Schulte, Dr. · Contact
  • LMU Klinikum Großhadern
    München, 81377, Germany
    Recruiting
    • Danmei Zhang, Dr. med. · Contact
  • Klinikum rechts der Isar TU München
    München, 81675, Germany
    Recruiting
    • Patrick Wenzel, Dr. · Contact
  • Klinikum Oldenburg AöR
    Oldenburg, 26133, Germany
    Recruiting
    • Andrea Renzelmann, Dr. · Contact
  • Krankenhaus Barmherzige Brüder Regensburg
    Regensburg, 93049, Germany
    Recruiting
    • Anke Schlenska-Lange, Dr. · Contact
08

References and documents

Individual participant data

Plan to share: No — No IPD will be shared

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2025 (actual). Primary completion is estimated for Dec 2030, 61 months after the start.

Of 147 non-industry phase 2 interventional studies under Cholangiocarcinoma, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 65. This study's planned 61 months is above that.

Counting every sponsor, half of 173 studies reached it within 46 months; a quarter within 29 and three quarters within 65.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 2, 2025
First posted
Dec 3, 2025
StartActual
Nov 18, 2025
Primary completionEst.
Dec 2030
CompletionEst.
Dec 2031
Last update
Aug 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 12, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07260175
Lead sponsor
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Collaborators
Servier Deutschland GmbH, Servier Affaires Médicales
Responsible party
Sponsor
First posted
Dec 3, 2025
Start date
Nov 18, 2025
Primary completion
Dec 2030 (estimated)
Completion
Dec 2031 (estimated)
Last update
Aug 12, 2026

Study contacts

Thorsten Götze, Prof. Dr.
Contact
Goetze.Thorsten@KHNW.DE
+49 69 76 01 ext. 4187
Johanna Riedel, Dr.
Contact
riedel.johanna@ikf-khnw.de
+49 69 5899 787 ext. 57
Salah Al-Batran, Prof. Dr.
study director · Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Thorsten Götze, Prof. Dr.
principal investigator · Krankenhaus Nordwest GmbH

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ivosidenib

Start the discussion